February 4, 2019/Cancer/News & Insight

Electronic Brachytherapy: Is It a Viable Option?

Why experts advise against it for breast, skin and gynecologic cancers


Traditional brachytherapy involves placing a radioactive source inside or on the surface of a patient’s body to more directly target a cancer or at-risk site. Used alone or in combination with external beam radiation therapy, it is standard of care for several types of malignancies.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Traditional brachytherapy techniques are categorized as low dose rate, pulsed or high dose rate, based on how the radiation sources decay. They can be left in the body permanently, such as with radioactive seeds to treat prostate cancer, or temporarily, such as with implants or applicators used to treat gynecologic or breast cancers.

While it is effective, isotope-based brachytherapy comes with strict regulations and costs associated with managing radioactive sources. That’s partly why a new form of brachytherapy, electronic brachytherapy (EB), has gained prominence in the past 10 years.

EB uses electrically generated X-rays rather than radioactive isotopes. It is not regulated by the Nuclear Regulatory Commission, doesn’t require as much shielding (due to lower energies) and, as such, can be easy to administer.

“EB is intended to be an alternative form of brachytherapy,” says Cleveland Clinic radiation oncologist Chirag Shah, MD. “However, how that radiation is generated and delivered is markedly different than traditional brachytherapy. Its dosing and clinical implications are still being studied.”

In 2018, the American Brachytherapy Society appointed a group of brachytherapy experts, including Dr. Shah, to establish guidelines for using EB. Based on a literature review and their clinical experience, the group published a consensus statement in Brachytherapy.

A lot of unknowns

In the statement, the group revealed significant gaps in data about EB, even though it has been studied in:

Breast cancer. Using EB for partial breast irradiation showed good local control and acceptable toxicity in one study of nearly 1,000 women with early-stage breast cancer. Smaller studies indicated the same. However, few and only very small studies have tracked patients long-term (five years or longer).

Skin cancer. There are significant data supporting the use of brachytherapy for small skin cancers, but the use of EB, specifically, has not been studied long-term. Also, very little data compare EB with other radiation therapy or surgical techniques, and studies have focused mostly on older patients.

Gynecologic cancer. While it’s feasible to use EB to deliver radiation to the vaginal cuff (after removal of the cervix and uterus), only very small studies have evaluated its effectiveness. Larger studies of brachytherapy for gynecologic cancer have not included EB.

“We found that there weren’t a lot of data studying EB in a prospective, randomized way, as with traditional brachytherapy,” says Dr. Shah. “And we can’t extrapolate from other brachytherapy techniques to EB. It’s not certain you’ll always get the same dose delivered in the same way as traditional techniques, so we can’t be sure about clinical outcomes, toxicity and other factors.”

More data on EB from a larger number of patients, with longer follow-up, are needed.

Unproven potential

Why is research in EB lacking? It could be because it’s not as widely used as traditional brachytherapy techniques.


Interest in EB may be greater in smaller centers not able to offer traditional brachytherapy due to regulatory and cost limitations, notes Dr. Shah — not in large brachytherapy programs that have other resources.

Until EB gains broader acceptance in the medical community and begins to be included in more long-term national trials, physicians can’t know how it could and should be used.

“EB could be a viable brachytherapy option, just not yet,” says Dr. Shah. “For now, our recommendation is not to use EB outside of clinical registries or trials.”

Feature image: 3D structure of a melanoma cell derived by ion abrasion scanning electron microscopy. Source: National Cancer Institute, created by Sriram Subramaniam


Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust